An embodiment of the present disclosure provides an extracellular matrix-based bioadhesive as an adhesive in the form of a composition including an extracellular matrix-containing hydrogel and a gelatin curing agent, wherein the extracellular matrix-containing hydrogel is gelatinized. Since the extracellular matrix-based bioadhesive according to an embodiment of the present disclosure has the same or similar rheological properties as gelatin, the bioadhesive has flowability at a temperature of 30° C. or higher and may be evenly and easily applied to a lesion site in the body. In addition, the extracellular matrix-based bioadhesive according to an embodiment of the present disclosure may adhere well to the lesion site because of a level of adhesive strength that is about 2 to 6 times higher than that of fibrin glue used as a commercial tissue adhesive. In addition, the extracellular matrix-based bioadhesive according to an embodiment of the present disclosure is based on a tissue-derived extracellular matrix, and thus includes a tissue-derived wound healing component or a tissue regeneration component, and may be used for wound healing or tissue regeneration in addition to bioadhesive applications.

A sealant syringe assembly includes a first syringe including a plurality of chambers and discharging a first solution which is a mixture of a buffer solution and compound powder; a reaction solution syringe including at least one chamber and discharging a reaction solution capable of reacting with the first solution; and a connector for connecting the first syringe and the reaction solution syringe to mix and discharge the first solution and the reaction solution. The first syringe includes three packing members provided inside the first syringe; a passage provided in the inner circumferential surface of the first syringe; and a plunger for providing a pressure to one of the packing members.

The present invention is concerned with a photosynthetic scaffold that delivers oxygen and its uses for tissue engineering and the treatment of ischemia.

The invention discloses a hemostatic composition comprising crosslinked gelatin in particulate form suitable for use in hemostasis, wherein the composition is present in paste form containing 15.0 to 19.5% (w/w), preferably 16.0 to 19.5% (w/w), 16.5 to 19.5% (w/w), 17.0 to 18.5% (w/w) or 17.5 to 18.5% (w/w), more preferred 16.5 to 19.0% (w/w) or 16.8 to 17.8% (w/w), especially preferred 16.5 to 17.5% (w/w), and wherein the composition comprises an extrusion enhancer.

Embodiments of the present disclosure include medical apparatus, and related methods thereof. The apparatus may include a longitudinally extending lead, at least one electrode, an anchor component, and a control module. The lead may include a distal end and a proximal end. The at least one electrode may be coupled to the lead, wherein the at least one electrode may be disposed on the distal end of the lead. The anchor component may be disposed in the lead proximate of the at least one electrode. The anchor component may include solder. The control module may be operably coupled to the proximal end of the lead and may be configured to deliver energy to the at least one electrode.

Proposed is a hemostatic sprayer for stopping a flow of blood from a bleeding portion of the human body, the hemostatic sprayer including a powder casing inside which an accommodation space is formed and which includes inlet and outlet ports, hemostatic in the form of powders being pre-stored in the accommodation space, and the inlet and outlet ports connecting thereto, and a receptacle inside which gas is compressed and pre-stored and which has a supply port on one side, the supply port separably connecting to the inlet port, wherein the supply port is open as a result of pressing by the powder casing, wherein, through the open supply port, the gas is supplied with a preset pressure toward the inlet port and flows into the accommodation space through the inlet port, and wherein the gas flowing is discharged together with the hemostatic through the outlet port while scattering the hemostatic.

Provided herein are novel methods and composition utilizing adipose tissue-derived stromal stem cells for treating fistulae.

The methods and compositions disclosed herein are effective in the promoting the reattachment of delaminated cartilage to bone. The methods (and related compositions) comprise the removal of the acellular layer of the delaminated cartilage thereby exposing the underlying chondrocyte cells thereby allowing the promotion of the reattachment of the delaminated cartilage.

The present invention is concerned with a photosynthetic scaffold that delivers oxygen and its uses for tissue engineering and the treatment of ischemia.

Disclosed herein are hemostatic materials and methods of production and use thereof.